Project Details
Description
In the rapidly moving area of gene therapy, fast adaptation to evolving knowledge is essential in order to better define ethical & safety provisions. The Euregenethy 2 will continue to focus on the ethical, safety and regulatory issue s related to clinical implementation of gene transfer technology in order to facilitate and help harmonise it.
Our current objectives are threefold:
(i) Fostering interaction between regulators, scientists and industry;
(ii) Offering a potential for a referral organisation following-up on evolving technologies;
(iii) Increase public accountability.
Means to achieve these goals are:
(1) Organisation of focused meetings and maintaining sessions at ESGT;
(2) Publication of an annual newsletter;
(3) Interactive web-page;
(4) Initiate safety & technology data-bases; GT-products & cell biology (including stem cells);
(5) Clinical trials data-base including a survey of successful trials.
Our current objectives are threefold:
(i) Fostering interaction between regulators, scientists and industry;
(ii) Offering a potential for a referral organisation following-up on evolving technologies;
(iii) Increase public accountability.
Means to achieve these goals are:
(1) Organisation of focused meetings and maintaining sessions at ESGT;
(2) Publication of an annual newsletter;
(3) Interactive web-page;
(4) Initiate safety & technology data-bases; GT-products & cell biology (including stem cells);
(5) Clinical trials data-base including a survey of successful trials.
Status | Finished |
---|---|
Effective start/end date | 1/12/01 → 30/09/05 |
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.